SGF-2(SGF-2) - _专利_临床

概要

基本信息

药物类型

重组蛋白

别名

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病

在研适应症-

非在研适应症

心脏衰竭

原研机构

Silver Creek Pharmaceuticals, Inc.

在研机构-

非在研机构

Silver Creek Pharmaceuticals, Inc.

权益机构-

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 SGF-2 相关的临床结果

登录后查看更多信息

100 项与 SGF-2 相关的转化医学

登录后查看更多信息

100 项与 SGF-2 相关的专利（医药）

登录后查看更多信息

1

项与 SGF-2 相关的文献（医药）

2020-07-01·Virus Research3区 · 医学

Genomic characterization of a novel virulent phage infecting Shigella fiexneri and isolated from sewage

3区 · 医学

Article

作者: Wang, Jingwei ; Lu, Han ; Liu, Xinchun ; Xiong, Wenbin ; Yan, Peihan

Shigella fiexneri phage SGF2 is a novel lytic phage isolated from a sewage sample. Morphological characterization indicates that phage SGF2 is a member of the Podoviridae family, producing virions with an isometric head (82.6 ± 8 nm diameter) and a short non-contractile tail (length 52 ± 8 nm). This phage specifically infected the Shigella fiexneri. One-step growth curves indicated that the burst period of phage SGF2 is 30 min, with an approximate burst size of 38. The full-length genome was sequenced and potential virulence genes were detected. We will discuss the potential application of phage SGF2 in phage therapy.

100 项与 SGF-2 相关的药物交易

登录后查看更多信息